Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

"We are thrilled to soon launch BYQLOVI, a truly clinically differentiated topical corticosteroid, into a U.S. market that now exceeds 7 million annual ophthalmic surgeries," said Mark L. Baum, Chief Executive Officer of Harrow. "With compelling efficacy, extraordinary safety, and patient‑friendly dosing, BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment." TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American ...